Biomedical Equipment Manager
Universal DX
Biomedical Equipment Manager
Universal DX
Liquid biopsy colorectal cancer detection test
About our Company:
Universal DX, Inc. is an international Company with a highly experienced team focused on cracking cancer’s code. Through our multi-omics and bioinformatics models, we have figured out how to read the disease’s signals in blood with high accuracy to detect cancer in its earliest stages. Starting with a colorectal cancer screening liquid biopsy test, we are building a multi-cancer platform that can identify the unique DNA regions associated with different types of cancers.
The Opportunity:
Universal Diagnostics (UDx) is seeking an Biomedical Equipment Manager to join our Lab Operations Team in the Dallas-Fort Worth, TX area. In this role, you will lead equipment operations through equipment readiness, scheduling, maintenance, calibration, qualification, and vendor service coordination for laboratory and manufacturing equipment. You will also lead equipment personnel, maintain required equipment documentation, and support operational readiness activities to help ensure equipment remains available, reliable, and ready for use as we continue scaling. You will work closely with cross functional teams, including Manufacturing, Assay Development, Automation, Quality, Facilities, IT, and Software to support ongoing laboratory and manufacturing activities.
How you’ll contribute:
What you’ll bring:
What we´ll offer:
Why Now?
This is an exciting time to be at Universal DX. We are growing rapidly and starting our US operations by building up our team, starting our lab and business operations, and establishing strategic partnerships.
We are looking for passionate changemakers to be a part of our journey in this expansive time for us.
Liquid biopsy colorectal cancer detection test
Universal Dx offers Signal-C®, a liquid biopsy test for colorectal cancer and advanced adenomas. The test analyzes a blood sample using multi-omics, computational biology, and machine learning to identify cancer signals, achieving 92% sensitivity and 94% specificity. Its collaboration with Quest Diagnostics and planned FDA approval help scale access through a major diagnostic network, differentiating it by scaled distribution and proven accuracy. The goal is to improve early detection, reduce cancer incidence and mortality, and make screening more accessible to the population.
Explore more opportunities at Universal DX